메뉴 건너뛰기




Volumn 83, Issue 3, 2006, Pages 266-270

Prevention of cytomegalovirus infection by valaciclovir after allogeneic bone marrow transplantation from an unrelated donor

Author keywords

Allogeneic BMT; Cytomegalovirus; Valaciclovir

Indexed keywords

VALACICLOVIR; VIRUS ANTIGEN; ACICLOVIR; ANTIVIRUS AGENT; DRUG DERIVATIVE; VALINE; VIRUS DNA;

EID: 33745941221     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.E0523     Document Type: Article
Times cited : (6)

References (29)
  • 1
    • 0022621521 scopus 로고
    • Risk factors for cytomegalovirus infection after human marrow transplantation
    • Myers JD. Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis. 1986;153:478-488.
    • (1986) J Infect Dis , vol.153 , pp. 478-488
    • Myers, J.D.1    Flournoy, N.2    Thomas, E.D.3
  • 2
    • 0025121087 scopus 로고    scopus 로고
    • Cytomegalovirus infections after allogeneic bone marrow transplantation
    • Winston DJ, Ho WG, Champlin RE. Cytomegalovirus infections after allogeneic bone marrow transplantation. Rev Infect Dis. 1999;12(suppl 7):S776-S792.
    • (1999) Rev Infect Dis , vol.12 , Issue.SUPPL. 7
    • Winston, D.J.1    Ho, W.G.2    Champlin, R.E.3
  • 3
    • 2942733177 scopus 로고    scopus 로고
    • Management of CMV infections: Recommendations from the infectious diseases working party of the EBMT
    • Ljungman P, Reusser P, de la Camara R, et al, for the Infectious Disease Working Party of the European Group for Blood and Marrow Transplantation. Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant. 2004;33:1075-1081.
    • (2004) Bone Marrow Transplant , vol.33 , pp. 1075-1081
    • Ljungman, P.1    Reusser, P.2    De La Camara, R.3
  • 4
    • 2942733565 scopus 로고    scopus 로고
    • Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation
    • Boeckh M, Fries B, Garrett NW. Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation. Pediatr Transplant. 2004;8(suppl 5):19-27.
    • (2004) Pediatr Transplant , vol.8 , Issue.SUPPL. 5 , pp. 19-27
    • Boeckh, M.1    Fries, B.2    Garrett, N.W.3
  • 5
    • 0027455417 scopus 로고
    • Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant
    • Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118:173-178.
    • (1993) Ann Intern Med , vol.118 , pp. 173-178
    • Goodrich, J.M.1    Bowden, R.A.2    Fisher, L.3    Keller, C.4    Schoch, G.5    Meyers, J.D.6
  • 6
    • 0027531101 scopus 로고
    • Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: Results of a placebo-controlled, double-blind trial
    • Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double-blind trial. Ann Intern Med. 1993;118:179-184.
    • (1993) Ann Intern Med , vol.118 , pp. 179-184
    • Winston, D.J.1    Ho, W.G.2    Bartoni, K.3
  • 7
    • 0029800728 scopus 로고    scopus 로고
    • Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study
    • Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88:4063-4071.
    • (1996) Blood , vol.88 , pp. 4063-4071
    • Boeckh, M.1    Gooley, T.A.2    Myerson, D.3    Cunningham, T.4    Schoch, G.5    Bowden, R.A.6
  • 8
    • 0025758922 scopus 로고
    • A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants: The City of Hope-Stanford-Syntex CMV Study Group
    • Schmidt GM, Horak D, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants: the City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med. 1991;324:1005-1011.
    • (1991) N Engl J Med , vol.324 , pp. 1005-1011
    • Schmidt, G.M.1    Horak, D.2    Niland, J.C.3    Duncan, S.R.4    Forman, S.J.5    Zaia, J.A.6
  • 9
    • 0034070233 scopus 로고    scopus 로고
    • Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation
    • Mori T, Okamoto S, Matsuoka S, et al. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 2000;25:765-769.
    • (2000) Bone Marrow Transplant , vol.25 , pp. 765-769
    • Mori, T.1    Okamoto, S.2    Matsuoka, S.3
  • 10
    • 0036272556 scopus 로고    scopus 로고
    • Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation
    • Mori T, Okamoto S, Watanabe R, et al. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29:777-782.
    • (2002) Bone Marrow Transplant , vol.29 , pp. 777-782
    • Mori, T.1    Okamoto, S.2    Watanabe, R.3
  • 11
    • 19944434167 scopus 로고    scopus 로고
    • Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic bone marrow transplantation: A single-center experience in Korea
    • Choi S-M, Lee D-G, Choi J-H, et al. Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic bone marrow transplantation: a single-center experience in Korea. Int J Hematol. 2005;81:69-74.
    • (2005) Int J Hematol , vol.81 , pp. 69-74
    • Choi, S.-M.1    Lee, D.-G.2    Choi, J.-H.3
  • 12
    • 21444434397 scopus 로고    scopus 로고
    • Risk-adapted preemptive therapy for cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation
    • Mori T, Aisa Y, Nakazato T, Okamoto S. Risk-adapted preemptive therapy for cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2005;81:439-440.
    • (2005) Int J Hematol , vol.81 , pp. 439-440
    • Mori, T.1    Aisa, Y.2    Nakazato, T.3    Okamoto, S.4
  • 13
    • 12144288318 scopus 로고    scopus 로고
    • Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation
    • Mori T, Mori S, Kanda Y, et al. Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;33:431-434.
    • (2004) Bone Marrow Transplant , vol.33 , pp. 431-434
    • Mori, T.1    Mori, S.2    Kanda, Y.3
  • 14
    • 0032838505 scopus 로고    scopus 로고
    • Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein
    • Talarico CT, Burnette TC, Miller WH, et al. Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein. Antimicrob Agents Chemother. 1999;43:1941-1946.
    • (1999) Antimicrob Agents Chemother , vol.43 , pp. 1941-1946
    • Talarico, C.T.1    Burnette, T.C.2    Miller, W.H.3
  • 15
    • 0029842170 scopus 로고    scopus 로고
    • Valaciclovir: A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections
    • Perry CM, Faulds D. Valaciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs. 1996;52:754-772.
    • (1996) Drugs , vol.52 , pp. 754-772
    • Perry, C.M.1    Faulds, D.2
  • 16
    • 0019720660 scopus 로고
    • The in vitro activity of acyclovir and related compounds against cytomegalovirus infections
    • Tyms AS, Scamans EM, Naim HM. The in vitro activity of acyclovir and related compounds against cytomegalovirus infections. J Antimicrob Chemother. 1981;8:65-72.
    • (1981) J Antimicrob Chemother , vol.8 , pp. 65-72
    • Tyms, A.S.1    Scamans, E.M.2    Naim, H.M.3
  • 17
    • 0023281112 scopus 로고
    • In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir
    • Cole NL, Balfour HH Jr. In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir. Diagn Microbiol Infect Dis. 1987;6:255-261.
    • (1987) Diagn Microbiol Infect Dis , vol.6 , pp. 255-261
    • Cole, N.L.1    Balfour Jr., H.H.2
  • 18
    • 0023873331 scopus 로고
    • Acyclovir for prevention of CMV infection and disease after allogeneic marrow transplantation
    • Meyers JD, Reed EC, Shepp DH, et al. Acyclovir for prevention of CMV infection and disease after allogeneic marrow transplantation. N Engl J Med. 1988;318:70-75.
    • (1988) N Engl J Med , vol.318 , pp. 70-75
    • Meyers, J.D.1    Reed, E.C.2    Shepp, D.H.3
  • 19
    • 0028274678 scopus 로고
    • Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation
    • European Acyclovir for CMV Prophylaxis Study Group
    • Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet. 1994;343:749-753.
    • (1994) Lancet , vol.343 , pp. 749-753
    • Prentice, H.G.1    Gluckman, E.2    Powles, R.L.3
  • 20
    • 0037089419 scopus 로고    scopus 로고
    • Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants
    • Ljungman P, de la Camara R. Milpied N. et al, and the Valacyclovir International Bone Marrow Transplant Study Group. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood. 2002;99:3050-3056.
    • (2002) Blood , vol.99 , pp. 3050-3056
    • Ljungman, P.1    De La Camara, R.2    Milpied, N.3
  • 21
    • 0037444029 scopus 로고    scopus 로고
    • Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation
    • Winston DJ, Yeager AM, Chandrasekar PH, Snydman DR, Petersen FB, Territo MC, and the Valacyclovir Cytomegalovirus Study Group. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis. 2003;36:749-758.
    • (2003) Clin Infect Dis , vol.36 , pp. 749-758
    • Winston, D.J.1    Yeager, A.M.2    Chandrasekar, P.H.3    Snydman, D.R.4    Petersen, F.B.5    Territo, M.C.6
  • 23
    • 0029075453 scopus 로고
    • HCMV pp65 antigenemia assay using indirect alkaline phosphatase staining method
    • Kurihara T, Hayashi J, Matusoka T, et al. HCMV pp65 antigenemia assay using indirect alkaline phosphatase staining method. Biomed Res. 1995;16:125-129.
    • (1995) Biomed Res , vol.16 , pp. 125-129
    • Kurihara, T.1    Hayashi, J.2    Matusoka, T.3
  • 24
    • 0027768955 scopus 로고
    • Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers
    • Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther. 1993;54:595-605.
    • (1993) Clin Pharmacol Ther , vol.54 , pp. 595-605
    • Weller, S.1    Blum, M.R.2    Doucette, M.3
  • 25
    • 0028883462 scopus 로고
    • Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans
    • Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother. 1995;39:2759-2764.
    • (1995) Antimicrob Agents Chemother , vol.39 , pp. 2759-2764
    • Soul-Lawton, J.1    Seaber, E.2    On, N.3    Wootton, R.4    Rolan, P.5    Posner, J.6
  • 26
    • 0034882831 scopus 로고    scopus 로고
    • Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: A single institution retrospective cohort analysis
    • Vusirikala M, Wolff SN. Stein RS, et al. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis. Bone Marrow Transplant. 2001;28:265-270.
    • (2001) Bone Marrow Transplant , vol.28 , pp. 265-270
    • Vusirikala, M.1    Wolff, S.N.2    Stein, R.S.3
  • 27
    • 6844258215 scopus 로고    scopus 로고
    • A randomized, double-blind trial of valacyclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection: AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group
    • Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valacyclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection: AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis. 1998;177:48-56.
    • (1998) J Infect Dis , vol.177 , pp. 48-56
    • Feinberg, J.E.1    Hurwitz, S.2    Cooper, D.3
  • 28
    • 0033551348 scopus 로고    scopus 로고
    • Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation
    • Lowance D, Neumayer H-H, Legendre CM, et al, for the International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med. 1999;340:1462-1470.
    • (1999) N Engl J Med , vol.340 , pp. 1462-1470
    • Lowance, D.1    Neumayer, H.-H.2    Legendre, C.M.3
  • 29
    • 22344434696 scopus 로고    scopus 로고
    • Blood and Marrow Transplant Clinical Trials Network Toxicity Committee consensus summary: Thromobotic microangiopathy after hematopoietic stem cell transplantation
    • Ho VT, Cutler C, Carter S, et al. Blood and Marrow Transplant Clinical Trials Network Toxicity Committee consensus summary: thromobotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:571-575.
    • (2005) Biol Blood Marrow Transplant , vol.11 , pp. 571-575
    • Ho, V.T.1    Cutler, C.2    Carter, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.